Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2016 - 2025)

Vanda Pharmaceuticals' Cash & Current Investments history spans 17 years, with the latest figure at $263.8 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 29.57% to $263.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $263.8 million, a 29.57% decrease, with the full-year FY2025 number at $263.8 million, down 29.57% from a year prior.
  • Cash & Current Investments hit $263.8 million in Q4 2025 for Vanda Pharmaceuticals, down from $293.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for VNDA hit a ceiling of $501.5 million in Q1 2023 and a floor of $263.8 million in Q4 2025.
  • Historically, Cash & Current Investments has averaged $401.8 million across 5 years, with a median of $395.3 million in 2021.
  • Biggest five-year swings in Cash & Current Investments: increased 21.08% in 2021 and later fell 29.57% in 2025.
  • Tracing VNDA's Cash & Current Investments over 5 years: stood at $432.8 million in 2021, then grew by 7.87% to $466.9 million in 2022, then dropped by 16.83% to $388.3 million in 2023, then decreased by 3.51% to $374.6 million in 2024, then fell by 29.57% to $263.8 million in 2025.
  • Business Quant data shows Cash & Current Investments for VNDA at $263.8 million in Q4 2025, $293.8 million in Q3 2025, and $325.6 million in Q2 2025.